| Literature DB >> 35064851 |
Duncan Short1, Rob J Fredericksen2, Heidi M Crane2, Emma Fitzsimmons2, Shivali Suri3, Jean Bacon4, Alexandra Musten4, Kevin Gough3, Moti Ramgopal5, Jeff Berry6, Justin McReynolds2, Abigail Kroch4, Brenda Jacobs5, Vince Hodge5, Divya Korlipara5, William Lober2.
Abstract
The PROgress study assessed the value and feasibility of implementing web-based patient-reported outcomes assessments (PROs) within routine HIV care at two North American outpatient clinics. People with HIV (PWH) completed PROs on a tablet computer in clinic before their routine care visit. Data collection included PROs from 1632 unique PWH, 596 chart reviews, 200 patient questionnaires, and 16 provider/staff questionnaires. During an initial setup phase involving 200 patients, PRO results were not delivered to providers; for all subsequent patients, providers received PRO results before the consultation. Chart review demonstrated that delivery of PRO results to providers improved patient-provider communication and increased the number of complex health and behavioral issues identified, recorded, and acted on, including suicidal ideation (88% with vs 38% without PRO feedback) and anxiety (54% with vs 24% without PRO feedback). In post-visit questionnaires, PWH (82%) and providers (82%) indicated that the PRO added value to the visit.Entities:
Keywords: HIV care; Implementation science; Patient-reported outcomes; Quality of life; Suicidal ideation
Mesh:
Year: 2022 PMID: 35064851 PMCID: PMC8783196 DOI: 10.1007/s10461-022-03585-w
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Primary objectives and data sources for the PROgress study
| Objectives | Data sources |
|---|---|
To understand and assess the number, proportion, and representativeness of individuals who are willing and able to successfully engage in the process | Numbers of PROs initiated and completed |
To assess the impact of the PRO intervention on the patient-provider interaction, clinic operation, and clinical/medical practice | Chart reviews, one-on-one interviewsa and structured surveys with participants (PWH, providers, and clinic staff) |
To assess the number, proportion, and representativeness of clinic personnel adopting the intervention | Post-interview structured surveys with participating providers and clinic staff |
To assess the degree to which the fidelity of PRO integration is upheld, including consistency of delivery, use as intended, and the time and cost of the intervention | One-on-one interviewsa and post-interview and post-training structured surveys with participating providers and clinic staff Time and cost assessment by designated site coordinators |
To assess the extent to which the intervention can be sustained over the longer term at the setting and individual levels | One-on-one interviewsa with participating providers and clinic staff |
To assess the acceptability of the intervention from the perspective of the stakeholders (patients, providers, and other clinic staff) | Acceptability E-scale and one-on-one interviews and structured surveys with participating PWH and providers |
PWH people with HIV, PRO patient-reported outcomes assessment
aQualitative analysis of one-on-one interviews is part of planned future work and is not described here
bA secondary objective was to obtain feedback from stakeholders on the wider project implementation strategies
Implementation strategies derived from reference to the Expert Recommendations for Implementing Change (ERIC) [23]
| Implementation strategies | Strategy details |
|---|---|
Assess for readiness and identify barriers and facilitators Conduct local needs assessment Develop a site-specific action plan | At the outset, a site visit assessment will be conducted to observe clinic operation and meet with salient pathway stakeholders to promote engagement, identify concerns and challenges (such as capacity barriers), and explore feasible pathway adaptations that will enable integration We will understand the process and logistics of current clinic flow and how the process can be implemented; this includes understanding the patient journey, options for timing of PRO data collection, and any logistical considerations (e.g., printer locations if the provider uses a printout of the data) Ahead of implementation, a site-specific action plan will be created for implementation, including the process/flow and choice of PROs to meet clinic needs |
Promote adaptability and integrate the PRO process within the current workflow and clinic operation | The implemented process will be designed to improve patient management and will consider how this can dovetail and improve the current workflow. For example, how can the implementation support or enhance current workflow, such as adopting timings to suit clinic patterns and gathering data that are needed for both clinical and site needs in a more efficient way and not have a detrimental effect on the fidelity of the intervention |
Involve leadership from the outset Involve clinic staff Identify and prepare champions | We will seek buy-in from senior stakeholders to ensure that we have full endorsement and commitment to implement The clinical teams will be involved in the decision-making process regarding the PRO intervention, including the PRO domain content, feedback form design, and levels of risk to flag to minimize the need for incremental iterative changes, which can be time-consuming and cause confusion A role will be defined to champion this process—this may be a research coordinator or similar |
Conduct educational meetings Develop educational materials | Educational materials and training will be conducted to ensure that stakeholders understand the value and process of the PRO data collection intervention |
Provide IT infrastructure to enable PRO integration | Integrating the process will involve provision of tablet computers with functionality for data collection, the development of a summary sheet of PRO outcomes, and the provision of tablet computers and printers |
IT information technology, PRO patient-reported outcomes assessment
Patient-reported outcomes assessment domains and instruments included in PROgress
| Tool | MSCC | SMH |
|---|---|---|
| Housing | Yes | Yes |
| Nutrition (Canadian Nutrition Screening Tool) [ | Yesa | Yes |
| Depression (PHQ-9) [ | Yes | Yes |
| Anxiety (HIV symptoms inventory) [ | Yes | Yes |
| Adherence (VAS) | Yes | Yes |
| Satisfaction with HIV medications (HATQoL) [ | Yes | Yes |
| Nicotine use | Yes | Yes |
| Alcohol use (AUDIT-C) [ | Yes | Yes |
| Substance use (ASSIST) [ | Yes | Yes |
| Gender identity | Yes | Yes |
| Sexual risk behavior (SRBI) [ | Yes | Yes |
| Sexual orientation | Yes | Yes |
| Intimate partner violence (IPV-4) [ | Yes | Yes |
| Acceptability E-scale [ | Yes | Yes |
| Other current healthcare | No | Yes |
| Affordability of medication | No | Yes |
| Sex-enhancing substance use, “Chemsex” | No | Yes |
ASSIST Alcohol, Smoking and Substance Involvement Screening Test, AUDIT-C Alcohol Use Disorders Identification Test for Consumption, HATQoL HIV/AIDS-Targeted Quality of Life, IPV-4 Intimate Partner Violence-4, MSCC Midway Specialty Care Center, PHQ-9 Patient Health Questionnaire 9, SMH St Michael’s Hospital, SRBI Sexual Risk Behavior Inventory, VAS visual analog scale
aAt MSCC, only the weight loss item was included
Fig. 1Example of patient-reported outcomes assessment provider feedback summary (based on a fictional patient). AUDIT-C Alcohol Use Disorders Identification Test for Consumption, DOB date of birth, HATQoL HIV/AIDS-Targeted Quality of Life, IPV intimate partner violence, MRN medical record number, PHQ-9 Patient Health Questionnaire 9
Overview of evaluation tools used in the PROgress study
| Evaluation tool/method | Study phase | Administered | Participants | n | Measured | Remuneration |
|---|---|---|---|---|---|---|
| PRO training evaluation | Preparation | At conclusion of training | Staff and providers | 18 | Perceived quality of PRO training | None |
| Acceptability E-scale survey | Setup and delivery | Within PRO assessment | Patients | 1102 | Acceptability and usability of PRO platform | None |
| PIPPI survey | Delivery | On-site, after care visit | Patients | 200 | Perceived impact of PROs on patient-provider communication | US $10 |
| Brief clinical/non-clinical staff post-interview survey | Delivery | At conclusion of one-on-one interview | Staff and providers | 16 | Perceived utility of PROs in practice | None |
| Chart review | Setup and delivery | NA, performed by on-site research coordinator | Patients | 596 | Incidence of provider documentation of issues identified by PRO and subsequent referral | NA |
NA not applicable, PIPPI perceived impact of PROs on patient-provider interaction, PRO patient-reported outcomes assessment
Fig. 2PROgress study design and participants. PWH people with HIV, PRO patient-reported outcomes assessment. aReasons for not initiating the PRO were language barriers (n = 68), felt not needed/useful (n = 22), literacy barriers (n = 21), not in mood (n = 13), vision problems (n = 11), perceived length (n = 10), cognitive problems (n = 7), too sick (n = 3), tired of it (n = 1), other reason (n = 6), and no reason given (n = 19). b2 participants did not complete the PRO for unknown reasons. cIncluding 1102 completed Acceptability E-scales. dQualitative analysis of one-on-one interviews is part of planned future work and is not described here. eSetup phase = without PRO feedback to providers; delivery phase = with PRO feedback to providers
Demographic characteristics, symptoms, and behaviors of participating PWH included in the chart reviews and post-visit structured surveys
| Parameter, n (%) | Chart reviews | Post-visit survey (N = 200) | ||
|---|---|---|---|---|
| Setup phase (N = 200) | Delivery phase (N = 396) | Total (N = 596) | ||
| Age | ||||
| < 30 | 24 (12) | 44 (11) | 68 (11) | 16 (8) |
| 30 to < 40 | 34 (17) | 83 (21) | 117 (20) | 37 (18) |
| 40 to < 50 | 35 (18) | 74 (19) | 109 (18) | 41 (20) |
| 50 to < 60 | 50 (25) | 85 (21) | 135 (23) | 50 (25) |
| ≥ 60 | 55 (28) | 110 (28) | 165 (28) | 56 (28) |
| Sex at birth | ||||
| Male | 137 (68) | 272 (69) | 409 (69) | 144 (72) |
| Female | 63 (32) | 124 (31) | 187 (31) | 56 (28) |
| Race | ||||
| Black | 83 (42) | 171 (43) | 254 (43) | 81 (40) |
| White | 79 (40) | 153 (39) | 222 (37) | 76 (38) |
| Asian | 9 (4) | 15 (4) | 24 (4) | 10 (5) |
| Other/NSa | 29 (15) | 57 (14) | 86 (14) | 33 (17) |
| Ethnicity | ||||
| Hispanic | 13 (6) | 29 (7) | 42 (7) | 11 (6) |
| Symptoms and behaviors | NR | |||
| Dissatisfaction with ARTb | 54 (27) | 97 (24) | 151 (25) | |
| ART adherence ≤ 90% | 36 (18) | 58 (15) | 94 (16) | |
| Any IPV | 25 (13) | 24 (6) | 49 (8) | |
| Suicidal ideation | 13 (7) | 26 (7) | 39 (7) | |
| Anxiety | 62 (31) | 142 (36) | 204 (34) | |
| Depression | 61 (31) | 99 (25) | 160 (27) | |
| Nutrition (CNST)c | 85 (43) | 147 (37) | 232 (39) | |
| Hazardous drinking (AUDIT-C) | 40 (20) | 107 (27) | 147 (25) | |
| Substance use (ASSIST) | 24 (12) | 57 (14) | 81 (14) | |
ART antiretroviral therapy, ASSIST Alcohol, Smoking and Substance Involvement Screening Test, AUDIT-C Alcohol Use Disorders Identification Test for Consumption, CNST Canadian Nutrition Screening Tool, HATQoL HIV/AIDS-Targeted Quality of Life, IPV intimate partner violence, NR not recorded, NS not specified, PWH people with HIV, PRO patient-reported outcomes assessment, ROS review of systems
aIncluding aboriginal, First Nations, Middle Eastern, mixed race, and Native American
bResponded “some of the time” or greater on one or both of the following HATQoL items: “…taking my [HIV] medicine has been a burden” and “…taking my [HIV] medicine has made it hard to live a normal life”
cWeight loss without trying on CNST or ROS item 177 re weight loss, or 176 re weight gain/fat
Fig. 3Patient-reported outcomes assessment responses to HIV/AIDS-Targeted Quality of Life satisfaction with HIV medications questions
Impact of PROs on provider behavior: documentation of symptoms, behaviors, and referrals in the setup phase (without PRO feedback to providers, N = 200) and delivery phase (with PRO feedback to providers, N = 396)
| Symptom/behavior | PRO feedback to providersa | Nb | Documentation | Referral | ||
|---|---|---|---|---|---|---|
| n (%)c | n (%)c | |||||
| Any IPVe | Without | 25 | 8 (32) | 0.77 | NA | NA |
| With | 24 | 9 (38) | NA | |||
| Sexual risk behaviorf | Without | 14 | 4 (29) | 1.0 | NA | NA |
| With | 20 | 7 (35) | NA | |||
| Adherence ≤ 90% | Without | 36 | 30 (83) | 0.77 | NA | NA |
| With | 58 | 50 (86) | NA | |||
Dissatisfaction with ART regimen (HATQoL)g | Without | 54 | 23 (43) | 0.09 | NA | NA |
| With | 97 | 56 (58) | NA | |||
| Suicidal ideatione,h | Without | 13 | 5 (38) | 0.002 | 7 (54) | 0.48 |
| With | 26 | 23 (88) | 18 (69) | |||
| Anxietyh | Without | 62 | 15 (24) | < 0.001 | 11 (18) | 0.008 |
| With | 142 | 77 (54) | 52 (37) | |||
| Depressionh | Without | 61 | 26 (43) | 0.08 | 19 (31) | 0.40 |
| With | 99 | 57 (58) | 38 (38) | |||
| Nutrition (CNST)h,i | Without | 85 | 31 (36) | 0.58 | 31 (36) | 0.58 |
| With | 147 | 60 (41) | 60 (41) | |||
| Hazardous drinking (AUDIT-C)h | Without | 40 | 12 (30) | 0.40 | 6 (15) | 0.38 |
| With | 107 | 25 (23) | 10 (9) | |||
| Substance use (ASSIST)h | Without | 24 | 7 (29) | 0.80 | 3 (12) | 1.0 |
| With | 57 | 20 (35) | 7 (12) | |||
ART antiretroviral therapy, ASSIST Alcohol, Smoking and Substance Involvement Screening Test, AUDIT-C Alcohol Use Disorders Identification Test for Consumption, CNST Canadian Nutrition Screening Tool, HATQoL HIV/AIDS-Targeted Quality of Life, IPV intimate partner violence, NA not applicable, PRO patient-reported outcomes assessment, ROS review of systems
aSetup phase = without PRO feedback to providers; delivery phase = with PRO feedback to providers
bSymptom endorsed in PRO assessment
cPercent of total endorsed
dFisher exact test
eProviders were alerted in both phases
fAt St Michael’s Hospital only
gResponded “some of the time” or greater on 1 or both of the following HATQoL items: “…taking my [HIV] medicine has been a burden” and “…taking my [HIV] medicine has made it hard to live a normal life”
hReferrals were counted as discussions
iWeight loss without trying on CNST or ROS item 177 re weight loss, or 176 re weight gain/fat
Fig. 4Results of structured surveys carried out during the delivery phase with A providers (N = 11) and B clinic staff (N = 5) to assess the perceived impact of PROs. PRO patient-reported outcomes assessment
Fig. 5Results of A PIPPI (N = 200) and B Acceptability E-scale (N = 1102) surveys to assess participants’ perceived impact and acceptability of PROs. aNumber of participants who responded to the question. bParticipants were asked to score the statements on a scale of 1 to 5. For panel A, 1 represented strong disagreement and 5 represented strong agreement. For panel B, 1 represented a low level of ease, satisfaction, and understanding and 5 represented a high level. *Mean scores significantly different between sites (P < 0.05, t test). MSCC Midway Specialty Care Center, PIPPI perceived impact of PROs on patient-provider interaction, PRO patient-reported outcomes assessment, SMH St Michael’s Hospital